Loading...
Loading...
--
Forest Laboratories
FRX and Gedeon Richter Plc. announced
that the U.S. Food and Drug Administration issued a complete
response letter regarding the New Drug Application (NDA) for
cariprazine, an atypical antipsychotic for the treatment of
schizophrenia and for the acute treatment of manic or mixed episodes
associated with bipolar I disorder in adults.
In the complete response letter, the FDA acknowledged that cariprazine
clearly demonstrated effectiveness in the treatment of schizophrenia and
mania associated with bipolar disorder. However, the Agency indicated
more information, including additional clinical trial data, would be
needed. “Given the complex pharmacokinetics and metabolism of
cariprazine, we believe this request was made to better define the
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in